TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Can a Dedicated Chronic Limb-threatening Ischaemia (CLTI) Clinic Improve Patient Self-reported Quality of Life

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All patients seen and assessed in the CLTI clinic~Exclusion Criteria:~* Patients without a confirmed diagnosis of CLTI~* Patients with chronic venous insufficiency~* Patients with diabetic foot infection~* Patients with significant cognitive impairment such that they are unable to answer the questions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 105 Years
- Healthy Volunteers: f

Study Arms:
- Pre-intervention (Type: None): This group comprises patients who have been referred into the CLTI clinic service prior to their first assessment. These patients will be given a structured outcome questionnaire like the EuroQoL 5D questionnaire that asks them to describe their symptoms
- Post-intervention (Type: None): This group comprises patients from the pre-intervention group who have undergone a revascularisation procedure. These patients will be given the same structured questionnaire to complete post procedurally.~They will also be invited to complete the same questionnaire at 12 months post revascularisation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Study With a Loading Dose of Clofazimine in Adult Patients With Nontuberculous Mycobacterial Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The participant is diagnosed with pulmonary or extrapulmonary NTM disease and is eligible for treatment with CFZ~* The participant is at least 18 years of age~* The participant has a body weight (in light clothing and with no shoes) of at least 45 kg~* The participant is able and willing to provide written, informed consent~Exclusion Criteria:~* The participant is in poor general condition where participation in the study cannot be accepted per discretion of the Investigator~* There is evidence showing the participant has clinically significant metabolic, gastrointestinal, or other abnormalities that could possibly alter the PK of CFZ~* The participant is diagnosed with cystic fibrosis~* The participant has a prolongation of the QTc interval, \> 450 milliseconds for males and \> 460 milliseconds for females, on the screening ECG~* The participant has abnormal alanine aminotransferase (ALT) and/or aspartate transferase (AST) levels of \> 3 times the upper limit of the laboratory reference range at screening~* The participant is pregnant or is using inadequate contraceptive measures (if applicable)~* The participant is breastfeeding (if applicable)~* The participant has a known or suspected, current drug or alcohol abuse, that is, in the opinion of the Investigator, sufficient to compromise the safety or cooperation of the patient~* The participant has as history of allergy/hypersensitivity to CFZ~* The participant has received clofazimine in the past 3 months before inclusion with the exception of short-term use of no more than 7 days in the period of 1 to 3 months before inclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Loading dose Clofazimine (Type: EXPERIMENTAL): All participants will receive an (experimental) oral loading dose regimen of 300 mg clofazimine (CFZ) once daily (= 3 capsules of 100 mg) for 4 weeks. Afterwards, all participants will continue with a standard oral dose of 100 mg clofazimine once daily (= 1 capsule of 100 mg) until a total 4 months of treatment with CFZ.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hormone Therapy in Treating Patients With Advanced Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the prostate~  * T1c-T2a-b, N1-2 or pN1-2 (after pelvic lymphadenectomy)~ * T2c-T4, N0-2~* Prior external radiotherapy for locally advanced prostatic carcinoma required~* Prior hormone therapy (6 months of combined androgen blockade) for locally advanced prostatic carcinoma required with PSA no greater than 150 ng/mL before administration~* No progressive disease after the 6 months of combined androgen blockage~* No stages T1c/T2a-b with a negative pelvic lymph nodes status that is assessed clinically or surgically~* No lymph node involvement to common iliac and/or periaortic lymph nodes (M1a)~* No external iliac lymph node metastasis more than 5 cm in greatest dimension (N3)~* No distant metastases~PATIENT CHARACTERISTICS:~Age:~* Any age~Performance status:~* WHO 0-2~Life expectancy:~* At least 5 years~Hematopoietic:~* Hemoglobin at least 10 g/dL~* WBC at least 2,000/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Not specified~Renal:~* Not specified~Other:~* No prior or concurrent cancers other than basal cell skin cancer~* No serious nonmalignant disease resulting in a life expectancy of less than 5 years~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior biologic therapy for prostate cancer~Chemotherapy~* No prior chemotherapy for prostate cancer~Endocrine therapy~* See Disease Characteristics~Radiotherapy~* See Disease Characteristics~Surgery~* See Disease Characteristics

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with ankylosing spondylitis who are not responding well to conventional therapy and receive adalimumab will be enrolled in the survey~Exclusion Criteria:~* Contraindications according to the Package Insert~  * Patients who have serious infections~ * Patients who have tuberculosis~ * Patients with a history of hypersensitivity to any ingredient of Humira~ * Patients who have demyelinating disease or with a history of demyelinating disease~* Patients who have congestive cardiac failure

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Adalimumab (Type: None): Participants with ankylosing spondylitis (AS) receiving treatment with adalimumab (Humira) as prescribed by their physician.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Testing Different Messaging Approaches to Increase Activation of a HealthyFood Benefit in Adults With Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults over age 18~2. Vitality health members who have not yet enrolled in the Vitality HealthyFood benefit~3. Diagnosis of type 2 diabetes (based on registration for chronic benefits for type 2 diabetes)~4. Have registered on to Discovery Health/Vitality website in the past (marker of Internet access and availability of email address)~Exclusion Criteria:~* Anyone who does not meet above criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control Arm (Type: NO_INTERVENTION): This arm will represent current practice. This group will receive no contact from the research team. They may receive information regarding the benefit from the Vitality marketing team during the intervention period and can enroll in the benefit at any time during the study period.
- Diabetes-specific (Type: ACTIVE_COMPARATOR): This group will receive a message which simply cites the two specific benefits of the eating more healthy foods for individuals with diabetes. This message contains a link to start the enrolment process.
- Experience of another member (Type: ACTIVE_COMPARATOR): This group will receive a message that includes a quote from the perspective of a Vitality member with diabetes who uses the HealthyFood benefit. Given the need to standardise message content across study arms, the quote was written by the study team and not an actual member. The quote emphasizes the positive impact the benefit has had for the member-both the financial benefit, as well as the two specific diabetes health benefits.
- Input from a diabetes expert (Type: ACTIVE_COMPARATOR): This group will receive a message that includes a quote from a South African physician who specializes in diabetes. The quote emphasises the financial benefit and the two specific diabetes health benefits of the HealthyFood program included in the other messages. It concludes with the doctor's recommendation of the benefit for all individuals with diabetes.
- Enhanced active choice (Type: ACTIVE_COMPARATOR): This group will receive a message whose first portion is identical to those in the diabetes-specific message group. The second portion of the message differs in that instead of just asking recipients to click on the provided link if interested, the message asks people to choose and click on one of following possible responses:~1. Yes! I want to active the HealthyFood benefit and get up to 25% cash back on the healthy food I buy at Pick n Pay or Woolworths~2. No, I'd prefer not to activate and continue paying full price for my healthy food purchases

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Predictive Value of the Cytocapacity Test Patients With Lymphoproliferative Diseases and High-dose Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Presence of histologically proven lymphoproliferative disease specified as Hodgkin's disease, non-Hodgkin's lymphoma (NHL) or multiple myeloma~* Indication of high-dose therapy and autologous peripheral blood stem cell transplantation~* Availability of a sufficient amount of blood stem cells (CD34+ cells \>= 2.0 x 106/kg)~* Age between 18 and 70 years~* High-dose therapy with one of the following high-dose regimes: Melphalan 140 mg/m2 or 200 mg/m2, BEAM, BEAC, BUCY or CBV (the last permitted according to amendment 2, see Section 9.8.1)~* Patient's written consent to participation in this trial~Exclusion Criteria:~* Previous high-dose therapy and blood stem cell transplantation except for melphalan 140 mg/m2 or 200 mg/m2 in patients with multiple myeloma who did not participate in the cytocapacity test previously (according to amendment 2, see Section 9.8.1).~* Known intolerance to lenograstim~* Out-patient therapy following high-dose therapy and blood stem cell transplantation~* Myocardial infarction \< 6 months prior to inclusion into the study~* Cardiac arrhythmias Lown IV b~* Clinically manifest cardiac insufficiency (\> NYHA II)~* Renal insufficiency with serum creatinine \> 2 mg%~* Hepatic diseases with elevated levels of transaminases and bilirubin greater than 3-fold above normal~* Severe infections (HIV, Hepatitis B/C)~* Severe psychiatric diseases~* Non-curative treatment of other malignoma within the past 5 years~* Pregnant women or women breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- A: lenograstim (Type: EXPERIMENTAL): total group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients admitted to the ISSEMYM Toluca Medical Center Arturo Montiel Rojas , diagnosed with COVID-19 confirmed by PCR.~* Patients in need of supplemental O2 with nasal prongs or reservoir-mask for satO2 \<90% and respiratory distress.~* With concomitant diseases such as cardiovascular disease, diabetes mellitus 2, hypertension, overweight or obesity BMI \<35.~* Both sexes.~* Over 30 years old.~* The patient tolerate oral feeding.~* Signing of the letter of informed consent.~Exclusion Criteria:~* Detachment from treatment.~* Admission to the ICU for any reason.~* Patients who do not tolerate the oral route.~* Reactions to treatment that compromise the health of patients.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- control group (Type: SHAM_COMPARATOR): Patients who received the standard diet
- Intervention group (Type: EXPERIMENTAL): Patients who received the nutritional support system (NSS) and the standard diet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Recombinant Human C1 Esterase Inhibitor in the Prevention of Contrast-induced Nephropathy in High-risk Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Estimated glomerular filtration rate (eGFR) of \<50 ml/min/1.73m2~* At least one of the following risk factors: diabetes mellitus, age at least 75 years, anemia (baseline hematocrit value less or equal 39% for men and less or equal 36% for women), congestive heart failure class III or IV by New York Heart Association classification, history of pulmonary edema.~Exclusion Criteria:~* Contraindications to the class of drugs under study (C1 esterase inhibitors), e.g. known hypersensitivity or allergy to class of drugs or the investigational product~* History of allergy to rabbits~* Current treatment with N-acetylcysteine, sodium bicarbonate, fenoldopam, mannitol (not applicable to mannitol serving as excipient in other medical drugs), dopamine or theophylline~* Women who are pregnant or breast feeding~* Multiple myeloma~* Acute decompensated heart failure (requiring hospital admission and treatment with supplemental oxygen, diuretics and/or vasodilator therapy) within two weeks prior to the date of coronary angiography~* Acute myocardial infarction (ST elevation or non-ST elevation myocardial infarction) within two weeks prior to the date of coronary angiography~* Dialysis~* Exposure to iodinated contrast media within seven days prior to the date of coronary angiography.~* Participation in another study with investigational drug within the 30 days preceding and during the present study~* Previous enrolment into the current study~* Enrolment of the investigators and their family members

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conestat alfa (Type: ACTIVE_COMPARATOR): Intravenous injection of Conestat alfa, for patients less than 84kg at a dose of 50 U/kg, and for patients of 84kg body weight or greater at a dose of 4200 U (2 vials, each diluted in 14ml sterile water).
- Sodium chloride 0.9% (Type: PLACEBO_COMPARATOR): Intravenous injection of sodium chloride 0.9%.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* More than 18 years of age.~* STEMI less than 12 hours from onset of pain. STEMI defined as as ST-segment elevation in 2 contiguous electrocardiographic leads of \>0.1 mV in V4 - V6 or limb leads II, III and aVF, or \>0.2 mV in lead V1 - V3.~* TIMI 0-1 in infarct related artery.~* Oral and written informed consent.~Exclusion Criteria:~* Multivessel disease defined by one or more stenoses \>70% in diameter in the non infarct related artery.~* Previous myocardial infarction.~* Stent trombosis.~* Previous CABG.~* Less than TIMI 2 following wiring and predilatation of the infarct related artery but prior to postconditioning or placebo treatment.~* Renal insufficiency (creatinin \>200).~* Pregnancy or lactation.~* Diabetic ketoacidose eller hypoglycemia (plasma glukose \< 2.5 mmol/l).~* Pancreatitis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Exenatide (Type: ACTIVE_COMPARATOR): 25 μg Byetta (Lilly, Exenatide) is added to 250 ml isotonic NaCl. Infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
- Saline (Type: PLACEBO_COMPARATOR): Isotonic saline infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, aged 18-80 years (both inclusive) at the time of signing informed consent~* Body mass index (BMI) between 18.5-39.9 kg/m\^2 (both inclusive)~* Subjects diagnosed clinically with type 2 diabetes mellitus for at least 180 days prior to the first screening visit~* For subjects with upper gastrointestinal (GI) disease: Diagnosed with chronic gastritis and/or gastroesophageal reflux disease (GERD) at screening~Exclusion Criteria:~* Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using a highly effective contraceptive method (adequate contraceptive measures as required by local regulation or practice). (Highly effective contraceptive methods are considered those with a failure rate less than 1% undesired pregnancies per year including surgical sterilisation, hormonal intrauterine devices (coil), oral hormonal contraceptives, sexual abstinence or a surgically sterilised partner)~* History of pancreatitis (acute or chronic)~* History of major surgical procedures involving the stomach potentially affecting absorption of trial product (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery)~* Unable or unwilling to refrain from smoking during the in-patient periods~* Any blood draw in excess of 50 mL in the past 30 days, or donation of blood or plasma in excess of 400 mL within 90 days of the first screening visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Semaglutide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study on Safety and Efficacy of an Oral Contraceptive in Long Cycles

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy women who desire contraception~* smokers ≤ 30 Years old~Exclusion Criteria:~* Contraindication against use of hormonal contraceptives

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Flexible (extended) treatment of EE20/DRSP (YAZ, BAY86-5300) (Type: EXPERIMENTAL): 3 cycles of treatment, each cycle comprising 120 days intended treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate (EE20) plus 3 mg drospirenone (DRSP) followed by a 4 day tablet-free interval. If 3 consecutive days of bleeding and/or spotting occurred during the 120 day treatment period, a 4 day tablet free interval was advised. The minimum period between 2 tablet free intervals was 24 days. After each 4 day tablet free interval, a new 120 day intended treatment period was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment.
- Fixed extended treatment of EE20/DRSP (YAZ, BAY86-5300) (Type: EXPERIMENTAL): 3 cycles of treatment, each cycle comprising 120 days uninterrupted treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone followed by a 4 day tablet free interval, 3 withdrawal bleeding episodes during one year of treatment were expected.
- Standard 24+4 treatment of EE20/DRSP (YAZ, BAY86-5300) (Type: ACTIVE_COMPARATOR): 13 cycles of treatment, each cycle comprising an intake of one tablet daily with 24 days of active tablets (20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone) followed by 4 days of placebo tablets, 13 withdrawal bleeding episodes during one year of treatment were expected.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete